Global Colitis Drugs and Companies Pipeline Review H1 2016

PUNE, INDIA, August 29, 2016 /EINPresswire.com/ -- Summary
‘Colitis - Pipeline Review, H2 2016’, provides an overview of the Colitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619304-colitis-pipeline-review-h2-2016

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/619304-colitis-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Colitis
- The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects
- The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Colitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Colitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/619304-colitis-pipeline-review-h2-2016

Key points in table of content
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Colitis Overview 10
Therapeutics Development 11
Pipeline Products for Colitis - Overview 11
Pipeline Products for Colitis - Comparative Analysis 12
Colitis - Therapeutics under Development by Companies 13
Colitis - Therapeutics under Investigation by Universities/Institutes 15
Colitis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Colitis - Products under Development by Companies 19
Colitis - Products under Investigation by Universities/Institutes 20
Colitis - Companies Involved in Therapeutics Development 21
Aerpio Therapeutics, Inc. 21
Akebia Therapeutics, Inc. 22
Amorepacific Corporation 23
Bayer AG 24
Bristol-Myers Squibb Company 25
Cosmo Pharmaceuticals S.p.A 26
Dr. Falk Pharma GmbH 27
EA Pharma Co Ltd 28
Euroscreen S.A. 29
Genfit SA 30
Immuron Limited 31
Innate Pharma S.A. 32
Peptinov SAS 33
Pfizer Inc. 34
Prokarium Limited 35
RDD Pharma Ltd. 36
Saniona AB 37
Synovo GmbH 38
Colitis - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AcTMP-1 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AKB-4924 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AKB-6899 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AN-346 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Antibody for Colitis - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
APY-0201 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BC-1215 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BMS-986104 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
budesonide - Drug Profile 58
Product Description 58
Mechanism Of Action 58

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619304

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.